Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology — Live Feedhttps://www.live-feeds.com/feed/novo-nordisk-to-pay-up-to-1-3-billion-for-nanexa-s-drug-delivery-technologyContinuously updated, source-cited coverage. Novo Nordisk to Pay Up to $1.3B for Nanexa Technologyhttps://www.live-feeds.com/feed/novo-nordisk-to-pay-up-to-1-3-billion-for-nanexa-s-drug-delivery-technologyhttps://www.live-feeds.com/feed/novo-nordisk-to-pay-up-to-1-3-billion-for-nanexa-s-drug-delivery-technology#u86326Sun, 27 Sep 2026 15:51:46 +0000Wegovy maker Novo Nordisk has agreed to pay up to $1.3 billion for Nanexa drug delivery technology, prompting a major surge in Nanexa shares. The agreement involves injection technology worth €1.17 billion, allowing Novo Nordisk to pursue long-acting obesity drugs. The multi-million-dollar deal unlocks long-acting obesity injectables for the pharmaceutical company, driving a significant 150 percent surge in the pharmaceutical stock on the market following the announcement of the injectables partnership.Why it mattersThe acquisition targets advanced drug delivery technology to support long-acti